Latham & Watkins Advises on Global Blood Therapeutics’ US$5.4 Billion Sale to Pfizer

Pfizer Inc. (NYSE: PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) have announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). The acquisition complements and further enhances Pfizer’s more than 30-year heritage in rare hematology and reinforces the company’s commitment to SCD by bringing expertise and a leading portfolio and pipeline with the potential to address the full spectrum of critical needs in this underserved community. Pfizer intends to continue to build on the companies’ shared commitment to and engagement with the SCD community.

Latham & Watkins LLP represents the Financial Advisors, J.P. Morgan Securities LLC and Centerview Partners LLC, in the transaction with a corporate deal team led by Orange Country and New York partner Charles Ruck, New York partner Robert Katz and Orange Country partner Daniel Rees, with Orange Country associate Taylor Ashton.